Gilead's idelalisib hat trick

Share this article:

Gilead's Zydelig, formerly known as idelalisib, has been approved. The FDA greenlighted the drug for three cancers: chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.

Zydelig is a first-in-class phosphoinositide 3-kinase delta inhibitor. The drug snared breakthrough status for the CLL indication. Despite the first-in-class status, the drug already has competition, including CLL drugs Imbruvica (Johnson & Johnson) and Roche's Gazyva.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.